Global Healthcare Study on Atopic Dermatitis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age14+
SponsorJulia Tatjana Maul
About this trial
The Global Healthcare Study on Atopic Dermatitis (GHSAD) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with atopic dermatitis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Signed General Consent Form, or equivalent document
Confirmed diagnosis of Atopic Dermatitis
Disqualifiers
Inability to provide informed consent.
Datasets with ambiguous or unclear diagnosis.
Trial population
Patient populations across world regions seen for atopic dermatitis.
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
9,600 Participants
are grouped into 1 trial groupGroup A: Global Healthcare Study on Atopic Dermatitis
Trial outcomes
Primary outcomes
1
Eczema Area and Severity Index (EASI)
Clinician-assessed measure of atopic dermatitis severity based on extent and severity of eczema signs; total score ranges from 0 to 72, with higher scores indicating more severe disease.
Time frame
Baseline and follow-up visits every 6-12 months for up to 5 years.Secondary outcomes
1
SCORing Atopic Dermatitis (SCORAD)
Clinician-assessed measure of atopic dermatitis severity incorporating extent, intensity, and subjective symptoms; total score ranges from 0 to 103, with higher scores indicating more severe disease.
Time frame
Baseline and follow-up visits every 6-12 months for up to 5 years.2
Dermatology Life Quality Index (DLQI)
Patient-reported measure of dermatology-specific quality of life; total score ranges from 0 to 30, with higher scores indicating greater impairment.
Time frame
Baseline and follow-up visits every 6-12 months for up to 5 years.3
Patient-Oriented Eczema Measure (POEM)
Patient-reported measure of atopic dermatitis symptoms and disease burden; total score ranges from 0 to 28, with higher scores indicating more severe disease.
Time frame
Baseline and follow-up visits every 6-12 months for up to 5 years.4
Peak Pruritus Numerical Rating Scale (PP-NRS)
Patient-reported assessment of peak itch severity on a numerical rating scale from 0 (no itch) to 10 (worst imaginable itch).
Time frame
Baseline and follow-up visits every 6-12 months for up to 5 years.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Julia Tatjana Maul
Lead sponsor
University of Zurich
Sponsor institution
University of Zurich
Collaborator
University Hospital, Zürich
Collaborator
Source ClinicalTrials.gov